Loading
Tenaya Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 07 Mar 2025.
Tenaya Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Tenaya Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Tenaya Therapeutics, Inc. logged 26 filings by 6 insiders.
The flow runs one way only: 19 sales worth €438k, from 4 insiders, and no purchase. One trade stands out by size: a sale of €161k from Column Group III GP, LP, disclosed on 26 February 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 26 filings here. Over the whole record (from 2021), the tally stands at 9 purchases and 43 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -90.6 m USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
82
Thresholds
n/a
Buy Volume
€68M
9 ops. · all time
Sell Volume
€774,724
43 ops. · all time
Who traded when
BuySaleFaraz Ali12 sales
Whittemore Tingley9 sales
Tomohiro Higa5 sales
Column Group III GP, LP1 buy3 sales
Goeddel David V1 buy
Saito Chihiro1 sale
Since the insiders bought
- +89.3%Entry US$0.51 · Close at T+365 US$0.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.41
Analyst consensus
5 analysts1.33/5
US$2.00Target US$3.20(+684%)US$5.00
Income statement
EBITDA-US$84.9M
Net income-US$90.6M0.0% margin
Valuation
PER (forward)-1.0x
P/Book1.3x
Beta2.88
Balance sheet & cash
Market capUS$91.6M
Total debtUS$10.8M
Free Cash Flow-US$68.9M
Debt / Equity6%
Profitability & ownership
ROE-121.9%
ROA-47.9%
% insiders0.5%
% institutions48.9%
Last declaration on 11 September 2026
Declarations82 total
49,000 shares0Common StockSEC:0001193125-26-389561:0
7,424 shares@ US$0.70980.0038% mcap100.0% of flowCommon StockSEC144:0001193125-26-354511
1,637 shares@ US$0.70980.0008% mcap1.2% of flowCommon StockSEC:0001193125-26-354517:0
1,871 shares@ US$0.70980.0010% mcap1.4% of flowCommon StockSEC:0001193125-26-354517:2
2,279 shares@ US$0.70980.0012% mcap1.7% of flowCommon StockSEC:0001193125-26-354517:3
309,228 shares@ US$0.61530.3% of flowCommon StockSEC:0001193125-26-076814:0
245,965 shares@ US$0.61490.2% of flowCommon StockSEC:0001193125-26-067007:0
611 shares@ US$0.64349.4% of flowCommon StockSEC:0001193125-26-055445:0
1,642 shares@ US$0.64321.1% of flowCommon StockSEC:0001193125-26-055439:0
161,422 shares@ US$0.81610.072% mcap0.2% of flowCommon StockSEC:0001193125-26-049028:0
29,250 shares0Common StockSEC:0001193125-26-039768:0
48,750 shares0Common StockSEC:0001193125-26-039763:0
1,367 shares@ US$1.3344.6% of flowCommon StockSEC:0001193125-25-284999:0
2,877 shares@ US$1.334.0% of flowCommon StockSEC:0001193125-25-284997:0
25 of 82 declarations
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ under the ticker TNYA. Headquartered in South San Francisco, California, it operates within one of the most important biotech clusters in the United States. Tenaya is focused on cardiac precision medicine, with a strategy centered on discovering and developing potentially curative therapies that address the underlying drivers of heart disease rather than simply managing symptoms.
The company was founded by cardiovascular scientists associated with the Gladstone Institutes and the University of Texas Southwestern Medical Center. From the outset, Tenaya has pursued an integrated platform spanning three interrelated pillars: gene therapy, cellular regeneration, and precision medicine. That platform approach is important from an investor perspective because it gives the company both a near-term clinical asset base and a longer-dated technology franchise. It also reflects a vertically integrated model, including target identification, AAV-based vector design, and in-house manufacturing capabilities, which can be strategically valuable in gene therapy.
Read moreShow less
Tenaya’s most advanced programs are TN-201 and TN-401. TN-201 is a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), while TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The pipeline also includes TN-301, a highly selective HDAC6 inhibitor being developed initially for heart failure with preserved ejection fraction (HFpEF). This mix of programs shows a dual focus: rare inherited cardiomyopathies, where clear genetic targets can support a more precise therapeutic hypothesis, and broader heart failure indications with substantial unmet medical need.
In competitive terms, Tenaya is operating in a highly specialized segment of biotech where differentiation depends on clinical proof of concept, durability of benefit, safety, manufacturability, and regulatory execution. The company is competing against other gene therapy and precision-cardiology developers, but its positioning is distinct because it is focused specifically on genetic drivers of cardiomyopathy and heart failure. As a clinical-stage company, however, it remains highly dependent on trial outcomes, FDA interactions, and financing access, which are material risks for equity investors.
Recent milestones have been important. In 2025 and early 2026, Tenaya reported encouraging interim clinical and preclinical data for TN-201 and TN-401, and it announced the rapid resolution and lifting of a clinical hold on TN-201, which was a meaningful de-risking event for that program. In January 2026, the company said it had raised $60 million in late 2025, extending its runway into mid-2027. For French-speaking investors, the key takeaway is that Tenaya is a high-risk, high-upside NASDAQ biotechnology story in the United States, with a differentiated scientific thesis but still substantial execution, regulatory, and funding risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
